Searching across hundreds of databases
Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
Integrated Clinical Trials is a virtual database currently indexing clinical trials from: EU Clinical Trials Register and ClinicalTrials.gov.
(last updated: Nov 28, 2022)
Clinical Trials Information| Database | Title | Recruitment | Conditions | Intervention | Sponsored By | Gender | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Clinicaltrials.gov | Soy Isoflavones Supplementation in Treating Women at High Risk For or With Breast Cancer | Active, not recruiting | BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer | Dietary Supplement, Other, Other, Procedure, Procedure, Other, Other, Procedure - soy isoflavones, placebo, questionnaire administration, magnetic resonance imaging, biopsy, immunohistochemistry staining method, laboratory biomarker analysis, mammography | University of Southern California, National Cancer Institute (NCI), California Breast Cancer Research Program, Other, NIH, Other | Female | 30 Years - 75 Years | N/A | Interventional | RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. The use of soy isoflavones supplements may prevent or treat early stage breast cancer. PURPOSE: This clinical trial studies soy isoflavones supplementation in treating women at high risk for or with breast cancer. | |
|
Clinicaltrials.gov | Stereotactic Radiosurgery Followed by Wedge Resection in Treating Patients With Early Stage Peripheral Non-small Cell Lung Cancer | Withdrawn | Recurrent Non-small Cell Lung Cancer, Stage IA Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer | Radiation, Procedure, Other, Other - stereotactic radiosurgery, therapeutic conventional surgery, laboratory biomarker analysis, quality-of-life assessment | University of Southern California, National Cancer Institute (NCI), Other, NIH | 18 Years - N/A | N/A | Interventional | This pilot clinical trial studies the side effects and how well stereotactic radiosurgery followed by wedge resection works in treating patients with early stage non-small cell lung cancer that is located in the outer, or peripheral, areas of the lung. Stereotactic radiosurgery, also known as stereotactic body radiation therapy, is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may kill more tumor cells and cause less damage to normal tissue. Wedge resection is a less invasive type of surgery for removal of the tumor and a small amount of normal tissue around it. Giving stereotactic radiosurgery followed by wedge resection may be a safe treatment option for patients who cannot receive standard treatment with lobectomy. | ||
|
Clinicaltrials.gov | Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients With Atypical Endometrial Hyperplasia or Endometrial Cancer | Withdrawn | Atypical Endometrial Hyperplasia, Endometrial Adenocarcinoma, Recurrent Endometrial Carcinoma, Stage IA Endometrial Carcinoma, Stage IB Endometrial Carcinoma, Stage II Endometrial Carcinoma, Stage IIIA Endometrial Carcinoma, Stage IIIB Endometrial Carcinoma, Stage IIIC Endometrial Carcinoma, Stage IVA Endometrial Carcinoma, Stage IVB Endometrial Carcinoma | Drug, Device, Other, Other - megestrol acetate, levonorgestrel-releasing intrauterine system, laboratory biomarker analysis, questionnaire administration | University of Southern California, National Cancer Institute (NCI), Other, NIH | Female | 18 Years - 44 Years | Phase 2 | Interventional | This randomized phase II trial studies how well megestrol acetate or levonorgestrel-releasing intrauterine system works in treating patients with atypical endometrial hyperplasia or endometrial cancer. Progesterone can cause the growth of endometrial cancer cells. Hormone therapy using megestrol acetate or levonorgestrel-releasing intrauterine system may fight endometrial cancer by lowering the amount of progesterone the body makes. It is not yet known whether megestrol acetate is more effective than levonorgestrel-releasing intrauterine system in treating atypical endometrial hyperplasia or endometrial cancer. | |
Clinicaltrials.gov | Oxaliplatin and Pemetrexed Disodium in Treating Patients With Refractory Hormone-Resistant Prostate Cancer | Completed | Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer | Drug, Drug, Other, Other, Genetic, Genetic - oxaliplatin, pemetrexed disodium, questionnaire administration, laboratory biomarker analysis, reverse transcriptase-polymerase chain reaction, polymorphism analysis | University of Southern California, National Cancer Institute (NCI), Other, NIH | Male | 18 Years - N/A | Phase 2 | Interventional | This phase II trial studies how well giving oxaliplatin and pemetrexed disodium together works in treating patients with refractory hormone-resistant prostate cancer. Drugs used in chemotherapy, such as oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving oxaliplatin together with pemetrexed disodium may kill more tumor cells. | |
|
Clinicaltrials.gov | Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer | Active, not recruiting | Breast Neoplasms, HER2/Neu Positive, Geriatric Health Services | Drug, Drug, Other, Other - Lapatinib, Trastuzumab, laboratory biomarker analysis, pharmacological study | City of Hope Medical Center, GlaxoSmithKline, Novartis, Other, Industry, Industry | 60 Years - N/A | Phase 2 | Interventional | This phase II trial studies the side effects and how well lapatinib ditosylate and trastuzumab work in treating older patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced) or to other parts of the body (metastatic). Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor to grow and spread. Others find tumor cells and help kill them or tumor cancer-killing substances to them. Giving lapatinib ditosylate together with trastuzumab may kill more tumor cells. | ||
|
Clinicaltrials.gov | Panobinostat and Fluorouracil Followed By Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer Who Did Not Respond to Previous Fluorouracil-Based Chemotherapy | Terminated | Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer | Drug, Drug, Drug, Procedure, Genetic, Genetic, Other, Genetic, Genetic, Genetic - panobinostat, fluorouracil, leucovorin calcium, biopsy, reverse transcriptase-polymerase chain reaction, western blotting, laboratory biomarker analysis, gene expression analysis, RNA analysis, polymorphism analysis | University of Southern California, Novartis, Other, Industry | 18 Years - N/A | Phase 1 | Interventional | Panobinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as fluorouracil and leucovorin calcium, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving panobinostat together with fluorouracil and leucovorin calcium may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and the best dose of giving panobinostat, fluorouracil, and leucovorin calcium together in treating patients with stage IV colorectal cancer who did not respond to previous fluorouracil-based chemotherapy. | ||
|
Clinicaltrials.gov | Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer | Completed | Breast Cancer | Biological, Drug, Drug, Drug, Drug, Other - trastuzumab, cyclophosphamide, doxorubicin hydrochloride, lapatinib ditosylate, paclitaxel, laboratory biomarker analysis | Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI), Dana-Farber Cancer Institute, GlaxoSmithKline, Other, NIH, Other, Industry | 18 Years - 120 Years | Phase 2 | Interventional | The purpose of this study is to study a new treatment for HER-2/neu (+) breast cancer. | ||
|
Clinicaltrials.gov | Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors | Completed | Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor, Pancreatic Polypeptide Tumor, Pulmonary Carcinoid Tumor, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Islet Cell Carcinoma, Somatostatinoma | Drug, Other - regorafenib, laboratory biomarker analysis | University of Southern California, National Cancer Institute (NCI), Other, NIH | 18 Years - N/A | Phase 2 | Interventional | This phase II trial studies regorafenib in treating patients with neuroendocrine tumors that have spread from the primary site (place where it started) to other places in the body. Regorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. | ||
|
Clinicaltrials.gov | Molecular Signatures of Relapse in Tissue Samples From Patients With Small Cell Lung Cancer Who Are Receiving Cisplatin and Etoposide | Withdrawn | Small Cell Lung Cancer | Other, Other - cytology specimen collection procedure, laboratory biomarker analysis | University of Southern California, National Cancer Institute (NCI), Other, NIH | 18 Years - N/A | Observational | This pilot research trial studies molecular signatures of the return of cancer after a period of improvement (relapse) in tissue samples from patients with small cell lung cancer who are receiving or planning to receive cisplatin and etoposide. Studying samples of tissue from patients with small cell lung cancer in the laboratory may help doctors learn more about the changes that occur in deoxyribonucleic acid (DNA) and identify biomarkers related to cancer relapse. | |||
|
Clinicaltrials.gov | Diffusion-Weighted MRI in Staging Patients With Localized Prostate Cancer | Completed | Adenocarcinoma of the Prostate, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer | Procedure, Other - diffusion-weighted magnetic resonance imaging, laboratory biomarker analysis | University of Southern California, National Cancer Institute (NCI), Other, NIH | Male | 18 Years - N/A | N/A | Interventional | This pilot clinical trial studies how well diffusion-weighted magnetic resonance imaging (MRI) works in staging patients with prostate cancer that has not spread to nearby lymph nodes or other parts of the body. New imaging techniques, such as diffusion-weighted MRI, may be a less invasive way of predicting the stage and grade of prostate cancer. | |
|
Clinicaltrials.gov | Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer | Active, not recruiting | Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer | Drug, Other, Other - phenelzine sulfate, laboratory biomarker analysis, questionnaire administration | University of Southern California, National Cancer Institute (NCI), Other, NIH | Male | 18 Years - N/A | Phase 2 | Interventional | This phase II trial studies phenelzine sulfate in treating patients with prostate cancer that has not spread to other parts of the body and has come back. Phenelzine sulfate is a type of antidepressant that works by decreasing the amount of a protein called monoamine oxidase (MAO). MAO drugs may have an anticancer effect in prostate cancer. | |
|
Clinicaltrials.gov | Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy | Terminated | Breast Cancer, Nausea, Vomiting | Drug, Drug, Other - granisetron transdermal system, fosaprepitant dimeglumine, laboratory biomarker analysis | University of Southern California, National Cancer Institute (NCI), Other, NIH | 18 Years - N/A | Phase 1 | Interventional | This clinical trial studies how well fosaprepitant dimeglumine and granisetron transdermal system work in preventing nausea and vomiting in patients with breast cancer undergoing chemotherapy. Antiemetic drugs may help lessen or prevent nausea and vomiting in patients treated with chemotherapy | ||
|
Clinicaltrials.gov | Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom Macroglobulinemia | Terminated | Waldenström Macroglobulinemia | Biological, Drug, Other - ofatumumab, bortezomib, laboratory biomarker analysis | Roswell Park Cancer Institute, National Cancer Institute (NCI), GlaxoSmithKline, Other, NIH, Industry | 18 Years - N/A | Phase 2 | Interventional | This phase II trial studies how well giving ofatumumab together with bortezomib works in treating patients with previously untreated Waldenstrom macroglobulinemia. Monoclonal antibodies, such as ofatumumab and bortezomib, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving ofatumumab together with bortezomib may be a better way to block cancer growth | ||
|
Clinicaltrials.gov | Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder | Terminated | Recurrent Bladder Cancer, Stage III Bladder Cancer, Stage IV Bladder Cancer, Transitional Cell Carcinoma of the Bladder | Drug, Drug, Other, Genetic, Other - docetaxel, lapatinib ditosylate, immunohistochemistry staining method, fluorescence in situ hybridization, laboratory biomarker analysis | University of Southern California, National Cancer Institute (NCI), GlaxoSmithKline, Other, NIH, Industry | 18 Years - N/A | Phase 2 | Interventional | This phase II trial studies how well giving docetaxel and lapatinib ditosylate together as second-line therapy works in treating patients with stage IV bladder cancer that cannot be removed by surgery. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving docetaxel and lapatinib ditosylate together may kill more tumor cells. | ||
|
Clinicaltrials.gov | Comprehensive Genomic Analysis in Tissue and Blood Samples From Young Patients With Lung Cancer | Completed | Non-small Cell Lung Cancer, Small Cell Lung Cancer | Other, Other - cytology specimen collection procedure, laboratory biomarker analysis | University of Southern California, Foundation Medicine, Addario Lung Cancer Medical Institute, National Cancer Institute (NCI), Other, Industry, Other, NIH | N/A - 39 Years | Observational | This research trial studies genomic analysis in tissue and blood samples from young patients with lung cancer. Identifying specific gene mutations (changes in deoxyribonucleic acid [DNA]) may help doctors tailor treatment to target the specific mutations and help plan effective treatment. | |||
|
Clinicaltrials.gov | Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer | Withdrawn | Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer | Biological, Drug, Drug, Other - ziv-aflibercept, leucovorin calcium, fluorouracil, laboratory biomarker analysis | University of Southern California, National Cancer Institute (NCI), Other, NIH | 18 Years - N/A | Phase 2 | Interventional | This phase II trial studies how long it takes colorectal cancer resistant to standard treatment to grow while receiving treatment with ziv-aflibercept, and how well adding fluorouracil and leucovorin calcium to ziv-aflibercept works in treating patients with stage IV colorectal cancer after they progress on ziv-aflibercept alone. Ziv-aflibercept may stop the growth of colorectal cancer by blocking the formation of tumor blood vessels. Fluorouracil and leucovorin calcium are drugs used in chemotherapy. Fluorouracil works to stop the growth of tumors cells by preventing the cells from growing and dividing. Leucovorin calcium helps fluorouracil work better. Adding fluorouracil and leucovorin calcium to ziv-aflibercept may be an effective treatment for patients who progress on ziv-aflibercept alone. | ||
|
Clinicaltrials.gov | Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma | Completed | Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Extraocular Extension Melanoma, Iris Melanoma, Metastatic Intraocular Melanoma, Mucosal Melanoma, Recurrent Intraocular Melanoma, Recurrent Melanoma, Stage IIC Melanoma, Stage IIIA Intraocular Melanoma, Stage IIIA Melanoma, Stage IIIB Intraocular Melanoma, Stage IIIB Melanoma, Stage IIIC Intraocular Melanoma, Stage IIIC Melanoma, Stage IV Intraocular Melanoma, Stage IV Melanoma | Biological, Biological, Biological, Biological, Biological, Drug, Drug, Other - gp100 antigen, tyrosinase peptide, recombinant MAGE-3.1 antigen, multi-epitope melanoma peptide vaccine, incomplete Freund's adjuvant, Montanide ISA 51 VG, agatolimod sodium, laboratory biomarker analysis | University of Southern California, National Cancer Institute (NCI), Other, NIH | 16 Years - N/A | Phase 2 | Interventional | This pilot phase II trial studies how well giving vaccine therapy works in treating patients with stage IIC-IV melanoma. Vaccines made from melanoma peptides or antigens may help the body build an effective immune response to kill tumor cells | ||
|
Clinicaltrials.gov | MET/VEGFR2 Inhibitor GSK1363089 and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone in Locally Advanced or Metastatic NSCLC That Has Not Responded to Previous Chemotherapy | Completed | Lung Cancer | Drug, Drug, Other - MET/VEGFR2 inhibitor Foretinib, erlotinib hydrochloride, laboratory biomarker analysis | NCIC Clinical Trials Group, GlaxoSmithKline, Other, Industry | 18 Years - N/A | Phase 1/Phase 2 | Interventional | RATIONALE: MET/VEGFR2 inhibitor Foretinib and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This randomized phase I/II trial is studying the side effects of erlotinib hydrochloride when given together with or without MET/VEGFR2 inhibitor Foretinib and to see how well it works in treating patients with locally advanced or metastatic non-small cell lung cancer that has not responded to previous chemotherapy. | ||
|
Clinicaltrials.gov | Resistance Training and Protein Supplementation for Prostate Cancer Survivors | Completed | Prostate Cancer | Behavioral, Dietary Supplement, Procedure, Other, Other, Other - exercise intervention, nutritional supplementation, quality-of-life assessment, questionnaire administration, pharmacological study, laboratory biomarker analysis | University of Southern California, National Cancer Institute (NCI), Other, NIH | Male | 50 Years - N/A | N/A | Interventional | This randomized pilot clinical trial studies resistance training and protein supplementation in increasing lean body mass in patients with prostate cancer receiving androgen deprivation therapy. Resistance training and protein supplementation may help improve quality of life in patients with prostate cancer receiving androgen deprivation therapy. | |
|
Clinicaltrials.gov | Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer | Terminated | HER2-positive Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer | Drug, Drug, Drug, Biological, Other - capecitabine, cyclophosphamide, lapatinib ditosylate, trastuzumab, laboratory biomarker analysis | University of Southern California, National Cancer Institute (NCI), Other, NIH | Female | 18 Years - N/A | Phase 2 | Interventional | This phase II trial studies how well capecitabine, cyclophosphamide, lapatinib ditosylate, and trastuzumab work in treating patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. Drugs used in chemotherapy, such as capecitabine and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving capecitabine and cyclophosphamide daily may kill more tumor cells. Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for growth. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of the tumor to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving capecitabine, cyclophosphamide, lapatinib ditosylate, and trastuzumab together may be an effective treatment for breast cancer. |
Welcome to the RRID Resources search. From here you can search through a compilation of resources used by RRID and see how data is organized within our community.
You are currently on the Community Resources tab looking through categories and sources that RRID has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.
If you have an account on RRID then you can log in from here to get additional features in RRID such as Collections, Saved Searches, and managing Resources.
Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:
If you are logged into RRID you can add data records to your collections to create custom spreadsheets across multiple sources of data.
Here are the facets that you can filter the data by.
If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.
